SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle's stock is under pressure following earnings results that sparked concerns about heavy AI-related spending and its impact on future profitability; the community is closely watching key support levels. Some believe this is an overreaction and a buying opportunity, while others fear the company's debt and cash flow issues could continue to weigh on the stock. Chatter suggests a broader reassessment of AI-exposed companies is underway as investors digest the implications of Oracle's report.

Rivian Automotive, Inc. engages in the design, development, and manufacture of category-defining electric vehicles and accessories. It operates through following segments: Automotive, Software and Services. The company was founded by Robert J. Scaringe in June 2009 and is headquartered in Irvine, CA.

Rivian Automotive Inc - Ordinary Shares - Class A

Rivian Automotive Inc

Rivian is trending due to its upcoming Autonomy and AI Day, with community members anticipating announcements around self-driving capabilities and in-house chip technology. Discussions also involve Rivian's potential to compete with Tesla and other EV makers, alongside mentions of production improvements and expansion plans. Overall, the community buzz reflects excitement and high expectations for Rivian's technological advancements in the EV sector.

The Trade Desk, Inc. engages in the provision of a self-service and cloud-based ad-buying platform. It operates through the United States and International geographical segments. The firm offers omnichannel advertising, audience targeting, solutions for identity, application programming interface (API), custom, and programmatic, measurement and optimization. The company was founded by Jeffrey Terry Green and David Pickles in November 2009 and is headquartered in Ventura, CA.

Trade Desk Inc - Ordinary Shares - Class A

Trade Desk Inc

Trade Desk is trending downwards as investors discuss customer losses and a recent analyst price cut, leading to concerns about its competitive position against larger platforms; the stock is nearing 52-week lows, sparking debates about potential takeover bids and whether it's a buying opportunity or a value trap given tax-loss selling pressures and potential Nasdaq 100 exclusion.

Mawson Infrastructure Group, Inc. engages in the provision of digital asset infrastructure services. The company was founded on February 10, 2012 and is headquartered in Midland, PA.

Mawson Infrastructure Group Inc

MIGI is trending due to anticipation surrounding its conference presentation and potential AI/HPC focus, with community members actively discussing a possible short squeeze and high price targets. Speculation about partnership announcements and positive updates are fueling the stock's volatility, while traders closely monitor key resistance levels and dilution concerns. Some traders suggest removing stop losses.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

BOIL is trending as traders weigh the impact of colder weather forecasts against high natural gas production and storage levels. Community discussions revolve around potential rallies, pullbacks, and the effects of contract rollovers on the ETF. Sentiment appears mixed, with some anticipating further upside and others bracing for a potential downturn.

Gemini Space Station, Inc. is a holding company, which offers a mobile and web based crypto asset exchange platform, proprietary wallet infrastructure and custody solutions, over-the-counter trading solutions tailored to institutions and professionals, a digital art auction platform, a proprietary United States dollar backed stablecoin, and a credit card product that offers crypto asset rewards on customer purchases. The company was founded by Tyler Winklevoss and Cameron Winklevoss in 2014 and is headquartered in New York, NY.

Gemini Space Station Inc. - Ordinary Shares- Class A

Gemini Space Station

GEMI is trending as traders discuss its potential in the prediction markets, fueled by a recent license approval and comparisons to Kalshi's valuation. Community members are pointing to strong buyer interest and potential breakout levels, while some highlight the company's ties to figures like Trump. The conversation also includes discussions around market capitalization and possible short squeezes.

Black Titan Corp. was formed for the purpose of effecting a merger between Titan Pharmaceuticals Inc. and TalenTec Sdn Bhd. It intends to explore and identify viable business opportunities. The company was founded on July 11, 2024 and is headquartered in Petaling Jaya, Malaysia.

Black Titan Corp.

Black Titan Corp. is trending as community members discuss its recent surge following news of its strategic entry into digital assets. Traders are actively debating holding strategies amidst volatility, with some pointing to dilution concerns and potential short squeeze opportunities. The stock's low float and potential for further news related to its digital asset framework are also fueling interest.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

SLV is trending as silver prices surge, driven by factors such as potential rate cuts and increasing industrial demand. Community members are discussing the possibility of a supply squeeze and potential for further gains, with some highlighting silver's outperformance compared to gold. Some traders are eyeing potential breakouts while remaining cautious of possible pullbacks.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

CADL is trending as investors discuss its potential in treating cancers, particularly after positive data in prostate cancer trials, while also citing undervaluation. The community is actively discussing the possibility of a short squeeze given the high short interest. Some also speculate about potential partnerships and acquisitions in the near future! LOAD!

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and the FC SAN business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broadcom is trending as investors anticipate earnings, especially in light of potential AI chip deals with major tech companies like Microsoft. Community discussions revolve around whether Broadcom can deliver strong guidance and justify its valuation amidst broader concerns of an AI spending slowdown. Bullish sentiment is fueled by expectations of significant AI revenue growth and the company's history of exceeding estimates.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The trial results showed for the first time that active immunotherapy targeting a-syn pathology could slow the progression of Parkinson’s disease.&nbsp;</li><li>The interim results from the study showed a 100% responder rate for all targets.</li><li>ACIU plans to seek regulatory feedback to potentially speed up the clinical development path towards registration.&nbsp; &nbsp;</li></ul>AC Immune SA (ACIU) shares surged on Thursday morning after the biopharma company announced positive results from the interim Phase 2 study of its early Parkinson’s disease treatment.&nbsp;The company said that the results of the VacSYn trial of ACI-7104.056 showed, for the first time, that targeting a-syn pathology with an active immunotherapy could possibly slow the progression of Parkinson’s disease.&nbsp;Shares of&nbsp;<a href="https://stocktwits.com/symbol/ACIU">ACIU</a> surged over 23% in pre-market trading after the announcement.&nbsp;“The interim Phase 2 data shows the potential of our ACI-7104.056 active immunotherapy to slow the progression of Parkinson’s disease and hold the promise of a tremendous step forward for millions of patients,” said Andrea Pfeifer, CEO of AC Immune SA. Pfeifer added that the strong results would be a basis for accelerating the development of the treatment.&nbsp;<h2 class="st-heading-2">Study Results</h2>The interim results from the study showed that the company’s new treatment had a 100% responder rate, meaning all participants had the expected immune response across all immunogenicity measures used.There were no clinically relevant or serious adverse effects to the drug apart from routine side effects such as injection site reactions, headaches, and fatigue, as reported by some participants.&nbsp;Final results from the Part 1 trial are expected in mid-2026, and the company plans to seek regulatory feedback to potentially speed up the clinical development path towards registration.&nbsp;<h2 class="st-heading-2">How Are Stocktwits Users Reacting?</h2>On Stocktwits, retail sentiment around ACIU jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume jumped to ‘extremely high’ from ‘normal’ levels at the time of writing.<figure class="image"><img style="aspect-ratio:1282/158;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_11_at_7_36_27_PM_png_161653af50.webp" alt="ACIU sentiment and message volume" width="1282" height="158"></figure>Shares of ACIU are up over 31% in the past six months.For updates and corrections, email newsroom[at]stocktwits[dot]com.

CHINA - 2025/10/02: In this photo illustration, the AC Immune logo is displayed on the screen of a tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

Why Is AC Immune Stock Up Over 23% Today?

ACIU shares surged over 23% after the company announced positive results from an interim Phase 2 study. 

Equity

FY2025 EPS Estimates for AC Immune Lifted by HC Wainwright

AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at HC Wainwright increased their FY2025 earnings per share (EPS) estimates for AC Immune in a report issued on Wednesday, November 5th. HC...

FY2025 EPS Estimates for AC Immune Raised by Leerink Partnrs

AC Immune (NASDAQ:ACIU - Free Report) - Investment analysts at Leerink Partnrs increased their FY2025 earnings per share (EPS) estimates for AC Immune in a research note issued on Wednesday, November...

AC Immune (ACIU) Reports Q3 Loss, Lags Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of +9.09% and -22.51%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

Alector (ALEC) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Alector (ALEC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Earnings Preview: AC Immune (ACIU) Q3 Earnings Expected to Decline

AC Immune (ACIU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Intellia Therapeutics (NTLA) Soars 19.7%: Is Further Upside Left in the Stock?

Intellia Therapeutics (NTLA) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.

New Strong Sell Stocks for August 6th

ACIU, ABEV and ALX have been added to the Zacks Rank #5 (Strong Sell) List on August 6, 2025.

AC Immune (ACIU) Reports Q2 Loss, Misses Revenue Estimates

AC Immune (ACIU) delivered earnings and revenue surprises of -25.00% and -57.30%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Royalty Pharma (RPRX) Earnings Expected to Grow: Should You Buy?

Royalty Pharma (RPRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AC Immune SA is a clinical-stage biopharmaceutical company, which engages in the discovery and development of therapeutic and diagnostic products for neurodegenerative diseases. It leverages proprietary technology platforms to discover, design, and develop novel, proprietary medicines for prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company was founded by Jean-Marie Lehn, Claude Nicolau, Roscoe Brady, Fred van Leuven, Ruth Greferath, Andrea Pfeifer, and Alexey V. Eleesiv on February 13, 2003 and is headquartered in Lausanne, Switzerland.

AC Immune SA

Bullish: S&P grinds higher

Choppy but up: buy dips

Sideways: fade the move

Bearish: this rally falls off

The Federal Reserve just announced a 0.25 percentage point interest rate cut at its December 10, 2025 meeting.​ Share your outlook on how the latest Federal Reserve interest rate cut will impact stocks and the S&P 500 over the next month.

How do you think today’s Fed rate cut impacts stocks over the next month?

ACIU
AC Immune SA

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest ACIU News

ACIUAC Immune SA